All the news Showing 10 of 228 articles from: TherapiesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources AbbVie combination cures 97% of genotype 3 hepatitis C Keith Alcorn / 21 April 2017 AbbVie's pangenotypic direct-acting antiviral combination of two drugs cured 95% of people with early-stage genotype 3 hepatitis C virus (HCV), the hardest genotype to treat, according to results of the ENDURANCE-3 ... Hepatitis C treatment can be provided successfully at syringe programme sites Liz Highleyman / 18 April 2017 Administering direct-acting antiviral therapy for people who inject drugs at a syringe exchange site led to high sustained response rates in a pilot study in New York City, researchers reported at the recent ... FDA approves Harvoni and Sovaldi for adolescents with hepatitis C Liz Highleyman / 10 April 2017 The US Food and Drug Administration (FDA) on 7 April approved the first direct-acting antivirals for the treatment of chronic hepatitis C virus (HCV) infection in adolescents aged 12 to 17 years. ... Glecaprevir/pibrentasvir for hepatitis C can be safely administered with common antiretrovirals Liz Highleyman / 13 March 2017 AbbVie's investigational glecaprevir/pibrentasvir treatment for hepatitis C is not expected to interact with or require dose adjustment when taken with commonly used antiretroviral regimens, offering a new option for people with HIV/hepatitis C ... DAA therapy cures most people with HIV/HCV co-infection with decompensated cirrhosis or liver transplants Liz Highleyman / 07 March 2017 People with HIV/hepatitis C virus (HCV) co-infection with liver cirrhosis or liver failure, and those who received liver transplants, saw high rates of sustained virological response using interferon-free direct-acting antiviral (DAA) therapy for ... Is DAA treatment for hepatitis C reducing the need for liver transplants? Liz Highleyman / 25 January 2017 People successfully treated for hepatitis are less likely to need liver transplants and less likely to die while on a transplant waiting list, according to studies presented at the 2016 ... Glecaprevir/pibrentasvir effective for people with hepatitis C and severe kidney disease Liz Highleyman / 22 December 2016 A two-drug pangenotypic regimen combining AbbVie's glecaprevir and pibrentasvir demonstrated a high sustained response rate for people with chronic hepatitis C who have severe kidney impairment, according to results from the EXPEDITION-4 study ... Curing hepatitis C may help reduce kidney disease progression Liz Highleyman / 20 December 2016 People who achieved sustained virological response to interferon-based hepatitis C treatment experienced significantly less decline in kidney function, especially if they had liver cirrhosis, according to study findings presented at the 2016 AASLD ... Generic sofosbuvir-based therapy under performs in real-world setting, but is use of suboptimal regimens the reason? Michael Carter / 09 December 2016 Generic sofosbuvir-based combinations may not perform as well as therapy based on branded sofosbuvir-containing regimens, according to result of a study conducted in Qatar and presented to the recent 2016 AASLD Liver Meeting. ... Six weeks of sofosbuvir/ledipasvir cures genotype 1 acute hepatitis C in people without HIV Liz Highleyman / 30 November 2016 A short course of sofosbuvir/ledipasvir (Harvoni) taken for 6 weeks cured 100% of HIV-negative people with genotype 1 acute hepatitis C virus (HCV) infection, including those with high viral loads, according to study results ... ← Prev12345...23Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive